pages:
-
A Phase 2, Open-Label, 2-C Cohort Study of INCB050465, A P13K@ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma With or Without Prior Exposure to a BTK Inhibitor (CITADEL-204)
-
A Phase 2, Open-Label, 2-Cohort, Multicenter Study of INCB050465, a PI13K Inhibitor, in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor (CITADEL-205)
-
A Phase 2, Open-Label, Extension Study to Evaluate the Long-
Term Safety and Efficacy of Ubenimex in Patients with
Pulmonary Arterial Hypertension (WHO Group 1)
-
A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination with Carfilzomib and Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma
-
A Phase 2, Open-label, Multicenter, Dose-Escalation and Expansion Study of Venetoclax in Combination with Pomalidomide and Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma
-
A Phase 2, Open-label, Multicenter, Exploratory Safety, Tolerability, Pharmacokinetic, and Efficacy Study of SPD489 in Preschool Children Aged 4-5 Years with Attention Deficit/Hyperactivity Disorder
-
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis or Invasive
Mucormycosis in Pediatric Subjects
-
A Phase 2, Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating
a Standard-dose and a High-dose Regimen in Patients With BRAFV600-Mutant Melanoma Brain
Metastasis
-
A Phase 2, Open-Label, Single-Arm Study of Pamiparib (BGB-290) for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Homologous Recombination Deficiency (HRD) (Beigene)
-
A Phase 2, Open-Label, Single-Arm Study of Single-Dose Lead-In and Neoadjuvant Trilaciclib and Chemotherapy in Patients with Early-Stage Triple Negative Breast Cancer (TNBC)
-
A PHASE 2, OPEN-LABEL, SINGLE-ARM, COHORT STUDY TO EVALUATE THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF SPARSENTAN TREATMENT IN PEDIATRIC SUBJECTS WITH SELECTED PROTEINURIC GLOMERULAR DISEASES (EPPIK)
-
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR
-
A Phase 2, Open-Label, Single-Arm, Sequential-Panel Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Posaconazole (POS, MK-5592) in Pediatric Participants From Birth to <2 Years of Age with Invasive Fungal Infection
-
A Phase 2, Open-label, Translational Biology Study of Momelotinib in Transfusion-Dependent Subjects
-
A Phase 2, Randomized, 3-Arm Study of Abiraterone Acetate alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix alone for Patients with Prostate Cancer with a Rise PSA or a Rising PSA and Nodal Disease Following Definitive ...
-
A Phase 2, Randomized, Controlled, Open-Label, Clinical Study of the Efficacy and Safety of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Patients with Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
-
A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients with Histologically Confirmed Nonalcoholic Steatohepatit
-
A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282, Administered for 12 Weeks in Patients with Primary Sclerosing Cholangitis (PSC)
-
A phase 2, randomized, double-blind study comparing Tremelimumab to placebo in Second- or third-line treatment of subjects with unresectable pleural or peritoneal malignant mesothelioma
-
A Phase 2, Randomized, Double-Blind Study of 0.01% and 0.03% Tacrolimus Cream Versus Cream Vehicle in the Treatment of Mild to Moderate Atopic Dermatitis in Adults
Fellowships, Supported Research, and Other Grants
-
A phase 2, randomized, double-blind, placebo-controlled study of ubenimex in patients with pulmonary arterial hypertension (WHO Group 1) (LIBERTY)
-
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Filgotinib and GS-9876 in Female Subjects with Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE)
-
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE SAFETY AND EFFICACY OF PF-04965842 IN SUBJECTS WITH MODERATE TO SEVERE PSORIASIS.
-
A Phase 2, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and
-
A Phase 2, Single Arm Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Rituximab in Patients with Previously Untreated Chronie Lymphocytic Leukemia with 17p Deletion
-
A Phase 2, Single-arm, Open-label, Study to Evaluate the Safety and Efficacy of MGTA-456 in Patients with Inherited Metabolic Disorders (IMD) Undergoing Hematopoietic Stem Cell (HSC) Transplantation (HSCT)
-
A Phase 2, Uncontrolled, Two-stage, Dose-escalations Cohort Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Clinical activity of OMS721 in Adults with Thrombotic Microangiopathies
-
A Phase 2,PlaceboControlled,Randomized,Double-Blind,Parallel-Arm Study to EvaluateEfficacy and Safety of BMS-986141For the Prevention of Recurrent Brain Infarction in Subjects receiving acetylsalicyclic acid(ASA)followingAcute Ischemic Stroke or TIA
-
A PHASE 2-3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY OF SELINEXOR (KPT-330) VERSUS PLACEBO IN PATIENTS WITH ADVANCED UNRESECTABLE DEDIFFERENTIATED LIPOSARCOMA (DDLS)
-
A Phase 2/3 Open-Label, Single-Arm Trial to Evaluate the Safety and Activity of Eculizumab in Pediatric Patients with Relapsing Neuromyelitis Optica Spectrum Disorder
pages: